These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8535785)

  • 1. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design.
    Ren J; Esnouf R; Hopkins A; Ross C; Jones Y; Stammers D; Stuart D
    Structure; 1995 Sep; 3(9):915-26. PubMed ID: 8535785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
    Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
    J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors.
    Ding J; Das K; Moereels H; Koymans L; Andries K; Janssen PA; Hughes SH; Arnold E
    Nat Struct Biol; 1995 May; 2(5):407-15. PubMed ID: 7545077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity.
    Kroeger Smith MB; Rouzer CA; Taneyhill LA; Smith NA; Hughes SH; Boyer PL; Janssen PA; Moereels H; Koymans L; Arnold E
    Protein Sci; 1995 Oct; 4(10):2203-22. PubMed ID: 8535257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors.
    Esnouf R; Ren J; Ross C; Jones Y; Stammers D; Stuart D
    Nat Struct Biol; 1995 Apr; 2(4):303-8. PubMed ID: 7540935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.
    Tantillo C; Ding J; Jacobo-Molina A; Nanni RG; Boyer PL; Hughes SH; Pauwels R; Andries K; Janssen PA; Arnold E
    J Mol Biol; 1994 Oct; 243(3):369-87. PubMed ID: 7525966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.
    Spence RA; Kati WM; Anderson KS; Johnson KA
    Science; 1995 Feb; 267(5200):988-93. PubMed ID: 7532321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High resolution structures of HIV-1 RT from four RT-inhibitor complexes.
    Ren J; Esnouf R; Garman E; Somers D; Ross C; Kirby I; Keeling J; Darby G; Jones Y; Stuart D
    Nat Struct Biol; 1995 Apr; 2(4):293-302. PubMed ID: 7540934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs).
    Barreca ML; Carotti A; Carrieri A; Chimirri A; Monforte AM; Calace MP; Rao A
    Bioorg Med Chem; 1999 Nov; 7(11):2283-92. PubMed ID: 10632038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational study of the interaction between TIBO inhibitors and Y181 (C181), K101, and Y188 amino acids.
    Freitas RF; Galembeck SE
    J Phys Chem B; 2006 Oct; 110(42):21287-98. PubMed ID: 17048958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular docking studies on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone (TIBO) derivatives as HIV-1 NNRT inhibitors.
    Sapre NS; Gupta S; Pancholi N; Sapre N
    J Comput Aided Mol Des; 2008 Feb; 22(2):69-80. PubMed ID: 18163186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
    Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
    Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
    Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.
    Balzarini J; Karlsson A; Pérez-Pérez MJ; Camarasa MJ; Tarpley WG; De Clercq E
    J Virol; 1993 Sep; 67(9):5353-9. PubMed ID: 7688822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution.
    Ding J; Das K; Tantillo C; Zhang W; Clark AD; Jessen S; Lu X; Hsiou Y; Jacobo-Molina A; Andries K
    Structure; 1995 Apr; 3(4):365-79. PubMed ID: 7542140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
    Debyser Z; Vandamme AM; Pauwels R; Baba M; Desmyter J; De Clercq E
    J Biol Chem; 1992 Jun; 267(17):11769-76. PubMed ID: 1376311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monte Carlo calculations on HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor 8-Cl TIBO: contribution of the L100I and Y181C variants to protein stability and biological activity.
    Smith MB; Lamb ML; Tirado-Rives J; Jorgensen WL; Michejda CJ; Ruby SK; Smith RH
    Protein Eng; 2000 Jun; 13(6):413-21. PubMed ID: 10877852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives.
    Ren J; Esnouf RM; Hopkins AL; Warren J; Balzarini J; Stuart DI; Stammers DK
    Biochemistry; 1998 Oct; 37(41):14394-403. PubMed ID: 9772165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hologram quantitative structure-activity relationships investigations of non-nucleoside reverse transcriptase inhibitors.
    Pungpo P; Hannongbua S; Wolschann P
    Curr Med Chem; 2003 Sep; 10(17):1661-77. PubMed ID: 12871115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis.
    de Vreese K; Debyser Z; Vandamme AM; Pauwels R; Desmyter J; de Clercq E; Anné J
    Virology; 1992 Jun; 188(2):900-4. PubMed ID: 1374986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.